Eton Pharmaceuticals Inc (ETON) USD0.001

Sell:$14.00Buy:$16.35$0.01 (0.06%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$14.00
Buy:$16.35
Change:$0.01 (0.06%)
Market closed | Prices delayed by at least 15 minutes
Sell:$14.00
Buy:$16.35
Change:$0.01 (0.06%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Key people

Sean E. Brynjelsen
President, Chief Executive Officer, Director
James R. Gruber
Chief Financial Officer, Treasurer, Company Secretary
Ipek Erdogan Trinkaus
Chief Commercial Officer
David C. Krempa
Chief Business Officer
Norbert G. Riedel
Independent Chairman of the Board
Jennifer Adams
Independent Director
Charles J. Casamento
Independent Director
Paul V. Maier
Independent Director
Click to see more

Key facts

  • EPIC
    ETON
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US29772L1089
  • Market cap
    $415.14m
  • Employees
    31
  • Shares in issue
    26.82m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.